Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Exmceuticals Inc V.ORR


Primary Symbol: C.EXM

Healthcare
EXMceuticals Inc. is a bio-sciences company that is focused on the production of cannabinoid formulations. The Company operates through its geographic segments, which include Canada, Portugal, Uganda and Netherlands. The Company’s subsidiaries include EXMceuticals Inc., EXMceuticals Holdings B.V, EXMceuticals Portugal, LDA and EXMceuticals Portugal II, Unipessoal Lda.


CSE:EXM - Post by User

Exmceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by queueon Apr 08, 1999 7:48am
62 Views
Post# 818930

1.1 million shares trading

1.1 million shares tradingWhat's up with this one.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities